Literature DB >> 11524491

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis.

A Martínez-Yélamos1, A Saiz, R Sanchez-Valle, V Casado, J M Ramón, F Graus, T Arbizu.   

Abstract

Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained at the first clinically isolated syndrome suggestive of MS. A positive 14-3-3 assay was the only independent predictor for a shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to 15) and to reach an Expanded Disability Status Scale (EDSS) > or =2 at the end of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8). The detection of the 14-3-3 protein in the CSF at the first neurologic event suggestive of MS may be a useful predictor of short-term evolution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524491     DOI: 10.1212/wnl.57.4.722

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

1.  14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis.

Authors:  Jérôme de Seze; Katel Peoc'h; Didier Ferriby; Tanya Stojkovic; Jean-Louis Laplanche; Patrick Vermersch
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

2.  CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS.

Authors:  A Martínez-Yélamos; A Rovira; R Sánchez-Valle; S Martínez-Yélamos; M Tintoré; Y Blanco; F Graus; X Montalban; T Arbizu; A Saiz
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

3.  Distal Axonal Proteins and Their Related MiRNAs in Cultured Cortical Neurons.

Authors:  Chao Li; Yi Zhang; Albert M Levin; Bao Yan Fan; Hua Teng; Moleca M Ghannam; Michael Chopp; Zheng Gang Zhang
Journal:  Mol Neurobiol       Date:  2018-07-28       Impact factor: 5.590

Review 4.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

Review 5.  Current and Future Biomarkers in Multiple Sclerosis.

Authors:  Jennifer Yang; Maysa Hamade; Qi Wu; Qin Wang; Robert Axtell; Shailendra Giri; Yang Mao-Draayer
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

Review 6.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

7.  Cerebrospinal fluid and blood biomarkers of neuroaxonal damage in multiple sclerosis.

Authors:  Irena Dujmovic
Journal:  Mult Scler Int       Date:  2011-05-02

Review 8.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

9.  Role of glial 14-3-3 gamma protein in autoimmune demyelination.

Authors:  De-Hyung Lee; Petra Steinacker; Silvia Seubert; Tanja Turnescu; Arthur Melms; Arndt Manzel; Markus Otto; Ralf A Linker
Journal:  J Neuroinflammation       Date:  2015-10-06       Impact factor: 8.322

10.  Imaging and clinical properties of inflammatory demyelinating pseudotumor in the spinal cord.

Authors:  Ying Wang; Min Wang; Hui Liang; Quntao Yu; Zhihui Yan; Min Kong
Journal:  Neural Regen Res       Date:  2013-09-15       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.